-$0.52 EPS Expected for Xencor Inc (NASDAQ:XNCR) This Quarter

Share on StockTwits

Equities research analysts expect that Xencor Inc (NASDAQ:XNCR) will announce ($0.52) earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have made estimates for Xencor’s earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.44). Xencor posted earnings per share of ($0.32) during the same quarter last year, which would indicate a negative year-over-year growth rate of 62.5%. The business is scheduled to issue its next earnings results on Monday, February 24th.

On average, analysts expect that Xencor will report full year earnings of $0.50 per share for the current year, with EPS estimates ranging from $0.34 to $0.67. For the next financial year, analysts expect that the firm will post earnings of ($1.67) per share, with EPS estimates ranging from ($2.63) to ($0.43). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Xencor.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.40. The business had revenue of $21.76 million during the quarter, compared to the consensus estimate of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%.

Several analysts recently issued reports on XNCR shares. Mizuho restated a “buy” rating on shares of Xencor in a research note on Tuesday, November 5th. Guggenheim initiated coverage on Xencor in a research report on Wednesday, November 20th. They set a “hold” rating for the company. ValuEngine downgraded Xencor from a “strong-buy” rating to a “buy” rating in a research report on Saturday. BidaskClub upgraded Xencor from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Zacks Investment Research downgraded Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $43.90.

Several large investors have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC lifted its position in shares of Xencor by 29.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 59,816 shares of the biopharmaceutical company’s stock worth $2,448,000 after buying an additional 13,553 shares during the last quarter. Comerica Bank bought a new stake in shares of Xencor during the 3rd quarter worth $1,610,000. Dupont Capital Management Corp bought a new stake in shares of Xencor during the 3rd quarter worth $339,000. First Trust Advisors LP bought a new stake in shares of Xencor during the 3rd quarter worth $2,472,000. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Xencor by 64.6% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock worth $1,097,000 after buying an additional 10,520 shares during the last quarter. Hedge funds and other institutional investors own 92.43% of the company’s stock.

XNCR opened at $39.65 on Wednesday. The business has a fifty day simple moving average of $36.93 and a 200 day simple moving average of $37.41. The company has a market capitalization of $2.31 billion, a PE ratio of -30.27 and a beta of 1.38. Xencor has a 1 year low of $27.75 and a 1 year high of $46.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.92 and a quick ratio of 8.92.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Story: Liquidity

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Chemung Financial Corp.  Shares Sold by Bowling Portfolio Management LLC
Chemung Financial Corp. Shares Sold by Bowling Portfolio Management LLC
Cisco Systems, Inc.  Shares Sold by Commerzbank Aktiengesellschaft FI
Cisco Systems, Inc. Shares Sold by Commerzbank Aktiengesellschaft FI
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
Central Garden & Pet Co  Shares Sold by State of Alaska Department of Revenue
Central Garden & Pet Co Shares Sold by State of Alaska Department of Revenue


© 2006-2020 Ticker Report